메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

2025 Aurora Prize for Awakening Humanity Awarded to Dr. Jamal E…

Head of Al Nao Hospital in Sudan recognized for sustaining critical medical care amid civil warand saving hundreds of lives NEW YORK, Nov. 7, 2025 -- The Aurora Humanitarian Initiative announced Thursday evening that Dr. Jamal Eltaeb has been named the 2025 Aurora Prize Laureate. The $1 million Aurora Prize for Awakening Humanity honors individuals who risk their lives to save others. This year, Aurora recognizes Dr. Eltaeb's extraordinary courage and steadfast dedication to providing care for those trapped in conflict. Amid Sudan's devastating civil war and the
- 김갑성 기자
- 2025-11-07 21:59
Brii Biosciences Announces Publication of Phase 2 ENSURE S…

Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy DURHAM, N.C. and BEIJING, Nov. 7, 2025 -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical need, today announced the publication of results from its Phase 2 ENSURE study in the peer-reviewed journal Nature Medicine. The study evaluates the efficacy and safet
- 김갑성 기자
- 2025-11-07 21:30
EBR Systems Achieves First Enrollments in the WiSE-UP Study for H…

The WiSE-UP post-approval study is gathering real-world evidence from commercially treated patients using the WiSE® left ventricular endocardial pacing (LVEP) system. Key Highlights: The first two patients have now been enrolled in the WiSE-UP post-approval study by Dr Devi Nair from St Bernards Heart & Vascular Center, Arkansas The EBR-sponsored study will evaluate real-world outcomes for heart failure patients receiving the FDA-approved WiSE® System for delivering LVEP in patients unable to receive traditional cardiac resynchronization therapy (CRT) T
- 김갑성 기자
- 2025-11-07 21:00
Coreline Soft Unveils AVIEW 2.0 at RSNA 2025: Next-Generation AI Pla…

CHICAGO and SEOUL, South Korea, Nov. 7, 2025 -- Coreline Soft will introduce its groundbreaking chest AI platform AVIEW 2.0 at RSNA 2025 (November 30–December 4, Chicago), demonstrating how unified AI automation is fundamentally transforming radiology workflows and elevating diagnostic precision across pulmonary, cardiac, and airway pathologies. AVIEW 2.0 represents a paradigm shift from task-specific tools to an integrated diagnostic ecosystem. The platform seamlessly combines lung-cancer screening (LCS), coronary-artery calcium scoring (CAC), and COPD quantifica
- 김갑성 기자
- 2025-11-07 21:00
'Coffee Diplomacy' at APEC: Korea-U.S. Startup Imunika Goes Vir…

Japan's newly appointed Foreign Minister Toshimitsu Motegi sparked an unexpected viral moment at APEC 2025 after stopping by Imunika — the official coffee sponsor of APEC 2025 Korea, a Korea–U.S. startup redefining "Wellness Specialty Coffee." SEOUL, South Korea and WASHINGTON, Nov. 7, 2025 -- A quiet exchange at the APEC 2025 Korea Summit became one of the event's most unexpected stories. Toshimitsu Motegi, Japan's newly appointed Foreign Minister — soon to help steer Japan–U.S. tariff negotiations — was filmed sampling Imunika, a small bio-fermented coffee startup that unex
- 김갑성 기자
- 2025-11-07 21:00
Pigeon Showcases Parenting Innovations Under "The Nes…

SHANGHAI, Nov. 7, 2025 -- During the 8th China International Import Expo (CIIE) at the National Exhibition and Convention Center, Pigeon unveiled its latest advances in feeding and baby care science under the theme "The Nest". 23 Years in China: Pigeon Expands from Local Innovation to Global Leadership Within the CIIE Consumer Goods exhibition area (Hall 6.1), Pigeon's baby feeding bottles have become a signature highlight. As the trusted global leader in high-quality, precision-engineered baby and maternity care products, Pigeon celebrates 23 years in C
- 김갑성 기자
- 2025-11-07 20:20
Alebund Presents Phase 3 Trial Results of AP301 at the Americ…

[ 메디채널 김갑성 기자 ] Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. The non-inferiority of AP301 to sevelamer carbonate in reducing serum phosphate levels was demonstrated. Overall, AP301 was safe and well-tolerated. The most common AEs were discolored feces and diarrhea. Diarrhea generally occurred early and resolved without treatment changes. No evidence of iron accumulation was observed with cumulative AP301
- 김갑성 기자
- 2025-11-07 20:00
Smartee Celebrates the Opening of its 4.0 Digital Orthodontic T…

JIAXING, China, Nov. 7, 2025 -- Smartee Denti-Technology has unveiled the Smartee Digital Orthodontic Technology Exhibition Hall, a 1,200-square-meter space dedicated to showcasing the company's innovations in clear aligner therapy and digital orthodontics. The event gathered a distinguished group of domestic orthodontic professionals, including Prof. Gang Shen and his orthodontic team, Ms. Paula Fabbie, Certified Orofacial Myologist and Examiner from IAOM (International Association of Orofacial Myology), Prof. Zhen Shi, Prof. Xue Feng, and Dr. Lei Shu, along with 21 orthodontists from
- 김갑성 기자
- 2025-11-07 18:05
Cranial Technologies Debuts NMPA-Cleared Infant Head Res…

SHANGHAI, Nov. 7, 2025 -- Cranial Technologies, a leading US medical device company specializing in the treatment of infant head shape conditions, officially introduced its flagship DOC Band® treatment in the Chinese market at the China International Import Expo (CIIE), taking place from November 5 to 10, 2025, in Shanghai. Cranial Technologies has treated over 400,000 infants across the United States and Europe. Its participation in CIIE marks a major milestone in the company's global expansion and its first entry into the Chinese market. "We are truly honored to parti
- 김갑성 기자
- 2025-11-07 15:58
Harbour BioMed and Evinova China Announce Strategic AI Co…

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 7, 2025 -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, announced a strategic collaboration in artificial intelligence (AI). Under the terms of the collaboration, Harbour BioMed and Ev
- 김갑성 기자
- 2025-11-07 14:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 21시 20분